Foamix Pharmaceuticals Ltd. Form SC 13G September 24, 2018

#### **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

#### **SCHEDULE 13G**

**Under the Securities Exchange Act of 1934** 

(Amendment No. )\*

Foamix Pharmaceuticals Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.16 per share

(Title of Class of Securities)

M46135105

(CUSIP Number)

**September 14, 2018** 

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

## Edgar Filing: Foamix Pharmaceuticals Ltd. - Form SC 13G

Rule 13d-1(c)

Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

# CUSIP No. M46135105

1	NAMES O	F REPORTING PERSONS
2	CHECK T	Advisors LLC HE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (b)
3	SEC USE	ONLY
4	CITIZENS	HIP OR PLACE OF ORGANIZATION
	Delaware 5	SOLE VOTING POWER
NUMB	ER OF	
SHA	RES 6	0 SHARED VOTING POWER
BENEFIC	CIALLY	
OWNI	ED BY	3,307,424 SOLE DISPOSITIVE POWER
EAC	CH 7	
REPOI	RTING	
PER	SON 8	0 SHARED DISPOSITIVE POWER
WI	ТН:	
9	AGGREGA	3,307,424 ATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10	3,307,424 CHECK B INSTRUC	OX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE TIONS)

- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
  - 6.3%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IA

# CUSIP No. M46135105

1	NAMES OF REPORTING PERSONS
2	Joseph Edelman CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) (b)
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America 5 SOLE VOTING POWER
N	NUMBER OF  O SHARES  6 SHARED VOTING POWER
BEN	NEFICIALLY
D	EACH  3,307,424  7 SOLE DISPOSITIVE POWER
K	PERSON  WITH:  8 SHARED DISPOSITIVE POWER
9	3,307,424 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10	3,307,424 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
  - 6.3%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN

# CUSIP No. M46135105

1	NAMES OF REPORTING PERSONS
2	Perceptive Life Sciences Master Fund, Ltd. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) (b)
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands 5 SOLE VOTING POWER
N	NUMBER OF  O SHARES  6 SHARED VOTING POWER
	NEFICIALLY  EACH 3,307,424  7 SOLE DISPOSITIVE POWER  REPORTING
	PERSON  WITH:  0  SHARED DISPOSITIVE POWER
9	3,307,424 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10	3,307,424 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
  - 6.3%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

### Item 1(a). Name of Issuer:

Foamix Pharmaceuticals Ltd. (the Issuer )

#### Item 1(b). Address of Issuer s Principal Executive Offices:

2 Holzman Street, Weizmann Science Park, Rehovot, Israel

#### Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the Reporting Persons ) are:

Perceptive Advisors LLC ( Perceptive Advisors )

Joseph Edelman (Mr. Edelman)

Perceptive Life Sciences Master Fund, Ltd. (the Master Fund )

## Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor

New York, NY 10003

#### Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company

Mr. Edelman is a United States citizen

The Master Fund is a Cayman Islands corporation

#### Item 2(d). Title of Class of Securities:

Ordinary Shares, par value NIS 0.16 per share (Ordinary Shares)

### Item 2(e). CUSIP Number:

M46135105

#### Item 3.

## Edgar Filing: Foamix Pharmaceuticals Ltd. - Form SC 13G

# If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

## Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 52,499,324 outstanding Ordinary Shares, as reported in the Issuer s prospectus supplement filed on September 14, 2018.

The Master Fund directly holds 3,307,424 Ordinary Shares. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities

directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.

#### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

## Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

# Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person</u>.

Not applicable.

## Item 8. <u>Identification and Classification of Members of the Group</u>.

Not applicable.

## Item 9. Notice of Dissolution of Group.

Not applicable.

#### Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

### **SIGNATURE**

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: September 24, 2018

### PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman

Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

# PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman

Title: Managing Member

**EXHIBIT 1** 

#### **AGREEMENT**

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: September 24, 2018

#### PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman

Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman

Title: Managing Member